Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345293
Status:
COMPLETED
Last Update Posted:
2016-04-18
First Post:
2006-06-26
Brief Title:
Dendritic Cell Vaccine Study DCPC3 for Prostate Cancer
Sponsor:
Rockefeller University
Organization:
Rockefeller University
Study Overview
Official Title:
A Phase III Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells DCPC3 Administered Subcutaneously to Prostate Cancer Patients
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and activity of DCPC3 a dendritic cell vaccine used as immunotherapy for prostate cancer The vaccine is made with each participants own immune cells obtained through blood donation Dendritic cells are known to activate other immune cells such as T cells that are able to mount an attack against cancer cells The dendritic cell vaccine will be administered as injections every 2 weeks over a course of 2 months
Detailed Description:
See Brief Summary
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None